My Stocks Explore Events Please signup to use this feature
Please signup to use this feature
Please signup to use this feature
Please signup to use this feature
Live today
{{event.ticker}} @{{event.event_utc_datetime | date:'h:mm a'}}
{{market.market_short_name}} {{market.last_price | number : 2}}
AlphaStreet

Want to join the conversation?


$TRIP {{ '2015-07-23T22:39:07+0000' | timeago}} • Webcast

$TRIP 2Q15 Q&A: Kelly of Oppenheimer asked about FX-neutral CPC pricing. Steve replied that some of revenue growth is coming from US, UK markets and those tend to be stronger CPC markets. We're probably seeing something in there. The auction is heating up. Mobile pricing over the course of 1H15 has got stronger and we're seeing nice trends there.

User ritesh salot {{ '2017-01-24T14:22:47+0000' | timeago}}

Baba

User Robert Smith {{ '2017-01-24T13:01:54+0000' | timeago}}

$JNJ down 2% in pre-market trading. Earnings beat expectations, but sales disappointed. Johnson is cautious on its outlook. How it will perform in the future?

User Charles Elliston {{ '2017-01-23T20:14:24+0000' | timeago}}

A federal judge has upheld the DOJ’s decision to block the $AET-$HUM merger.

User Josh Allan {{ '2017-01-23T20:10:30+0000' | timeago}}

$YHOO is reporting today after market close. Nobody cares about this stock.

User RC xNair {{ '2017-01-23T13:41:30+0000' | timeago}}

Excellent results from $MCD

$JNJ {{ '2017-01-24T15:20:58+0000' | timeago}} • Webcast

$JNJ, which acquired $ABT’s subsidiary Abbott Medical Optics in Sept. 2016 for $4.325Bil, said that it would close this acquisition in 1Q17. The company has now completed approx. 75% of its $10Bil share repurchase program and expects to complete this program during 1H17.

$MMM {{ '2017-01-24T15:15:09+0000' | timeago}} • Webcast

$MMM commented that its oral care business was down slightly in 4Q16. The decline was partially from softening end user demand and continued channel contractions in the oral care business. Additionally, $MMM added that inventory reduction in the channel also added to the sluggish oral care business.

$NEOG {{ '2017-01-24T15:10:10+0000' | timeago}} • Announcement

$NEOG terminated its agreement with $SNES related to the manufacturing and marketing of a rodenticide being developed by $SNES. The two firms had worked together since 2014, prior to the time when the $SNES product was approved by the U.S. Environmental Protection Agency.

$STBA {{ '2017-01-24T15:03:13+0000' | timeago}} • Announcement

$STBA's BoD declared a quarterly cash dividend of $0.20 per share. This is an increase of 5.3% compared to dividend of $0.19 per share declared in the same period in the prior year. The annualized yield using the Jan. 23, 2017 closing price of $37.12 is $2.2%. The dividend is payable on Feb. 23, 2017 to shareholders of record on Feb. 9, 2017.

$JNJ {{ '2017-01-24T15:02:44+0000' | timeago}} • Webcast

In pharma business, $JNJ expects to file 10 new products by 2019, each with at least $1Bil of potential sales. The company plans to file an additional 40 line extensions by 2019, 10 of which have more than $500MM in potential sales. In the medical devices business, $JNJ aims to return to above market growth by 2H17.